menu
    • menu

    Company profile for Dana-Farber Cancer Institute

    NEW Drugs in Dev: 147
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Since its founding in 1947, Dana-Farber Cancer Institute in Boston, Massachusetts has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Dana-Farber Cancer InstituteUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    450 Brookline Avenue Boston, MA 02215
    Telephone
    Telephone
    617-632-3000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.dana-farber.org/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Dana-Farber Study Backs Ignite Proteomics' RPPA for T-DXd
    Dana-Farber Study Backs Ignite Proteomics' RPPA for T-DXd

    20 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260420307974/en/Dana-Farber-Cancer-Institute-Study-Demonstrates-Predictive-Value-of-Ignite-Proteomics-RPPA-Platform-for-T-DXd-Enhertu-Therapy-in-Metastatic-Breast-Cancer-Patients

    BUSINESSWIRE
    20 Apr 2026
    Share Share
    Dana-Farber Ph 2 Shows Deep CAR T Responses in Multiple Myeloma
    Dana-Farber Ph 2 Shows Deep CAR T Responses in Multiple Myeloma

    20 Apr 2026

    // PRESS RELEASE

    https://www.dana-farber.org/newsroom/news-releases/2026/dana-farber-phase-2-trial-shows-deep-and-lasting-responses-to-car-t-cell-therapy-for-high-risk-smoldering-multiple-myeloma

    PRESS RELEASE
    20 Apr 2026
    Share Share
    Dana-Farber To Present 50+ Studies At AACR Annual Meeting 2026
    Dana-Farber To Present 50+ Studies At AACR Annual Meeting 2026

    19 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7187996

    FIRSTWORD PHARMA
    19 Apr 2026
    Share Share
    TAG1 Collaborates To Advance Targeted Alpha Therapies
    TAG1 Collaborates To Advance Targeted Alpha Therapies

    02 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tag1-announces-strategic-collaboration-to-advance-targeted-alpha-therapies-302700854.html

    PR NEWSWIRE
    02 Mar 2026
    Share Share
    Cancer vaccine prevents kidney cancer comeback in small trial
    Cancer vaccine prevents kidney cancer comeback in small trial

    07 Feb 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/cancer-vaccine-prevents-recurrence-advanced-kidney-cancer-small-trial

    FIERCE BIOTECH
    07 Feb 2025
    Share Share
    Fortress Biotech Doses First Patient In Phase 2 Triplex Trial
    Fortress Biotech Doses First Patient In Phase 2 Triplex Trial

    27 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/27/3015614/28889/en/Fortress-Biotech-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-Triplex-Vaccination-in-Stem-Cell-Donors-to-Reduce-CMV-Events-in-Recipients-of-HSCT.html

    GLOBENEWSWIRE
    27 Jan 2025
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search